BioCentury | Dec 10, 2020
Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

...details on its funding and pipeline.SoftBank fund leads $80M round for digital therapy play Pear Pear Therapeutics Inc....
...classify and sort cells. TARGETSTREM2 - Triggering receptor expressed on myeloid cells 2 BC Staff Nuance Biotech Hillhouse Capital Pear Therapeutics Atlas...
BioCentury | May 1, 2020
Product Development

April 30 Quick Takes: Pfizer to co-develop Valneva’s Lyme disease vaccine; plus Aravive-WuXi Biologics, Siga-BARDA, Pear, Capricor

...to expand the availability of digital health devices for psychiatric disorders during the COVID-19 pandemic, Pear Therapeutics Inc....
...VLA15-101 Oral TPOXX, oral tecovirimat (oral ST-246, oral Arestvyr, SIGA-246) reSET reSET-O CAP-1002 Valneva SE Pfizer Inc. Aravive Inc. WuXi Biologics Inc. Siga Technologies Inc. Pear Therapeutics Capricor...
BioCentury | Apr 20, 2020
Deals

Novartis expands digital focus with Amblyotech deal

...were not disclosed. Although Novartis backed out of a commercialization deal with digital therapeutics company Pear Therapeutics Inc....
BioCentury | Mar 27, 2020
Product Development

March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax

...FDA approves Pear’s cognitive behavioral insomnia therapy FDA approved Somryst from Pear Therapeutics Inc. to treat chronic insomnia...
...receptor tyrosine kinase LpxC - Bacterial UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase PDE-4 - Phosphodiesterase-4 Hongjiang Li, Staff Writer tepotinib (MSC2156119J) JZP-258 Pear Therapeutics Inc. Medimetriks...
BioCentury | Jan 3, 2020
Product Development

Digital learnings and modality visions: Novartis’ CEO on where R&D is headed

...October, 18 months after the partners had entered a co-promotion deal, Novartis’ Sandoz unit and Pear Therapeutics Inc....
...companies in looking at this. It’s been harder than maybe we originally expected. I think Pear Therapeutics’...
BioCentury | Jan 3, 2020
Emerging Company Profile

Click: personalized digital therapeutics for cognitive, neurobehavioral disorders

...other companies, according to BioCentury’s BCIQ database, are developing prescription digital therapeutics for neurobehavioral disorders. Pear Therapeutics Inc....
...effect of its digital therapeutic alone and in combination with antidepressants. Inhua Muijrers-Chen, Associate Editor Click Therapeutics Inc. Limbix Pear Therapeutics Inc....
BioCentury | Nov 16, 2019
Product Development

Navigating IP strategies in the world of digital therapeutics

...to Kailasanath, there's a trade-off between maintaining trade secrets and earning FDA clearance of approval. Pear Therapeutics...
BioCentury | Oct 30, 2019
Company News

Oct. 30 Company Quick Takes: Clinical hold for Zolgensma; plus Biogen-Alkermes, Roche’s satralizumab, Pear-Ironwood

...mAb against IL-6 are expected in 2020. Pear, Ironwood in digital deal for GI indications Pear Therapeutics Inc....
...on the market (see “Pear Gearing up to Sell Products Solo” ). BioCentury Staff IW-3718 Roche Alkermes plc Biogen Inc. Novartis AG Pear Therapeutics Inc. Ironwood...
BioCentury | Oct 16, 2019
Company News

Pear gearing up to sell products solo as Sandoz backs out of digital deal

...digital therapy pioneer believes it is well positioned to commercialize its flagship digital therapeutics independently. Pear Therapeutics Inc....
...partner for the reSET programs and will “absolutely execute reSET and reSET-O solo.” Lauren Martz, Associate Editor reSET reSET-O Pear Therapeutics Inc. Sandoz Novartis...
BioCentury | Aug 31, 2019
Product Development

Back to School 2019: Rules of the road for digital health

...or in the absence of pharmacotherapies, or that complement existing treatments. Two digital therapeutics, from Pear Therapeutics Inc....
...& biomarker Palo Alto Health Sciences Inc. Kirkland, Wash. Neurology Panic attacks Therapeutic & biomarker Pear Therapeutics Inc....
...digital health office at University of Texas Novartis AG (NYSE:NVS:SIX:NOVN) Markets reSET digital therapeutic from Pear Therapeutics...
Items per page:
1 - 10 of 33
BioCentury | Dec 10, 2020
Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

...details on its funding and pipeline.SoftBank fund leads $80M round for digital therapy play Pear Pear Therapeutics Inc....
...classify and sort cells. TARGETSTREM2 - Triggering receptor expressed on myeloid cells 2 BC Staff Nuance Biotech Hillhouse Capital Pear Therapeutics Atlas...
BioCentury | May 1, 2020
Product Development

April 30 Quick Takes: Pfizer to co-develop Valneva’s Lyme disease vaccine; plus Aravive-WuXi Biologics, Siga-BARDA, Pear, Capricor

...to expand the availability of digital health devices for psychiatric disorders during the COVID-19 pandemic, Pear Therapeutics Inc....
...VLA15-101 Oral TPOXX, oral tecovirimat (oral ST-246, oral Arestvyr, SIGA-246) reSET reSET-O CAP-1002 Valneva SE Pfizer Inc. Aravive Inc. WuXi Biologics Inc. Siga Technologies Inc. Pear Therapeutics Capricor...
BioCentury | Apr 20, 2020
Deals

Novartis expands digital focus with Amblyotech deal

...were not disclosed. Although Novartis backed out of a commercialization deal with digital therapeutics company Pear Therapeutics Inc....
BioCentury | Mar 27, 2020
Product Development

March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax

...FDA approves Pear’s cognitive behavioral insomnia therapy FDA approved Somryst from Pear Therapeutics Inc. to treat chronic insomnia...
...receptor tyrosine kinase LpxC - Bacterial UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase PDE-4 - Phosphodiesterase-4 Hongjiang Li, Staff Writer tepotinib (MSC2156119J) JZP-258 Pear Therapeutics Inc. Medimetriks...
BioCentury | Jan 3, 2020
Product Development

Digital learnings and modality visions: Novartis’ CEO on where R&D is headed

...October, 18 months after the partners had entered a co-promotion deal, Novartis’ Sandoz unit and Pear Therapeutics Inc....
...companies in looking at this. It’s been harder than maybe we originally expected. I think Pear Therapeutics’...
BioCentury | Jan 3, 2020
Emerging Company Profile

Click: personalized digital therapeutics for cognitive, neurobehavioral disorders

...other companies, according to BioCentury’s BCIQ database, are developing prescription digital therapeutics for neurobehavioral disorders. Pear Therapeutics Inc....
...effect of its digital therapeutic alone and in combination with antidepressants. Inhua Muijrers-Chen, Associate Editor Click Therapeutics Inc. Limbix Pear Therapeutics Inc....
BioCentury | Nov 16, 2019
Product Development

Navigating IP strategies in the world of digital therapeutics

...to Kailasanath, there's a trade-off between maintaining trade secrets and earning FDA clearance of approval. Pear Therapeutics...
BioCentury | Oct 30, 2019
Company News

Oct. 30 Company Quick Takes: Clinical hold for Zolgensma; plus Biogen-Alkermes, Roche’s satralizumab, Pear-Ironwood

...mAb against IL-6 are expected in 2020. Pear, Ironwood in digital deal for GI indications Pear Therapeutics Inc....
...on the market (see “Pear Gearing up to Sell Products Solo” ). BioCentury Staff IW-3718 Roche Alkermes plc Biogen Inc. Novartis AG Pear Therapeutics Inc. Ironwood...
BioCentury | Oct 16, 2019
Company News

Pear gearing up to sell products solo as Sandoz backs out of digital deal

...digital therapy pioneer believes it is well positioned to commercialize its flagship digital therapeutics independently. Pear Therapeutics Inc....
...partner for the reSET programs and will “absolutely execute reSET and reSET-O solo.” Lauren Martz, Associate Editor reSET reSET-O Pear Therapeutics Inc. Sandoz Novartis...
BioCentury | Aug 31, 2019
Product Development

Back to School 2019: Rules of the road for digital health

...or in the absence of pharmacotherapies, or that complement existing treatments. Two digital therapeutics, from Pear Therapeutics Inc....
...& biomarker Palo Alto Health Sciences Inc. Kirkland, Wash. Neurology Panic attacks Therapeutic & biomarker Pear Therapeutics Inc....
...digital health office at University of Texas Novartis AG (NYSE:NVS:SIX:NOVN) Markets reSET digital therapeutic from Pear Therapeutics...
Items per page:
1 - 10 of 33